• 
• 
• 
• 

FDA News and Drug Updates

Olaparib Tablet Receives New Indication in Ovarian Cancer

FDA News - September 2017

FDA News - August 2017

Supportive Care

A Taxing Consequence: Taxane Acute Pain Syndrome

Mark L. Zangardi, PharmD, BCOP

Helping Adolescents and Young Adults Confront Mortality

Meg Barbor, MPH

The Emerging Conversation About Physician-Assisted Death

Meg Barbor, MPH

View All Supportive Care Articles

Breast Cancer

No Advantage to Dual HER2 Blockade in Early-Stage Breast Cancer

Adding a Second Anti-HER2 Agent Appears Beneficial in Women with Early-Stage, HER2-Positive Breast Cancer at High Risk for Recurrence

Pembrolizumab Continues to Show Durable Activity in Triple-Negative Breast Cancer

View All Breast Cancer Articles

Conference Correspondent

Patient-Reported Outcomes Influence Radiation Guidelines

Healthy Lifestyle Improves Survival in Patients with Colon Cancer

8-Week Internet-Based Psychological Intervention Reduces Stress in Patients Newly Diagnosed with Cancer

View All Conference Correspondent Articles

Most Popular Articles

Left- vs Right-Sided Colon Cancers

Eric Van Cutsem, MD, PhD

Video Library - Colon Cancer

Intermountain Southwest Cancer Center Offers Comprehensive Cancer Care

TON - September 2017, Vol 10, No 5 - Cancer Center Profile

Serious Toxicities Associated with 5-Fluorouracil and Capecitabine: A Clinical Pharmacy Perspective

Amber Draper, PharmD, BCOP

RX Profiler - Uridine Triacetate: An Antidote to Life-Threatening 5-Fluorouracil and Capecitabine Toxicity - Supplements

Uridine Triacetate: An Antidote to Life-Threatening 5-Fluorouracil and Capecitabine Toxicity

Wen Wee Ma, MBBS

RX Profiler - Uridine Triacetate: An Antidote to Life-Threatening 5-Fluorouracil and Capecitabine Toxicity - Supplements